Consumer briefs

Share this article:
House Ways and Means Committee Chair Rep. Charles Rangel (D-NY) raised the prospect of pulling tax deductions on ads for pharmas, telling reporters he expects such a measure could reap a $37 billion windfall that would go toward healthcare reform. Rangel was quoted by Bloomberg as having said drug ads should not be subsidized by taxpayers because they encourage patients to demand medicines they don't need. “I do it,” said Rangel. “I go to the doctor and say, ‘Did you ever think about ordering this for me?' If he says no, I don't like him, because they promised me on TV that I have no problems at all.”

The FDA's rep has improved in the last year, according to a new Harris Interactive/HealthDay poll. Positive ratings for managing Rx drug recalls or withdrawals increased from 39% to 53%, but most still give the agency poor marks on ensuring food safety (56%) and drug safety (52%) and getting new drugs to market more quickly (54%).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?